Marksans Pharma reports Q1 FY26 gross profit 8.9% higher at Rs. 358.2 Cr
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
Under an exclusive distribution agreement, Sartorius Stedim Biotech will offer Nanotein’s lead products globally
Marksans Pharma gets USFDA nod for acid reflux drug
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Cupid reported total income of Rs. 64.75 crore in Q1 FY26 as compared to Rs. 44.03 crore in Q1 Fy25
The partnership aims to co-develop technologies set to revolutionize manufacturing of plasmid DNA (pDNA), a critical raw material for advanced medicines
The India Branded Business delivered a 5% YoY growth, reaching Rs. 599 crore in revenue for the quarter
Cenexi reports an EBITDA breakeven for the quarter
Subscribe To Our Newsletter & Stay Updated